| 俞 梅,廖珊珊,徐 佳,喻锦娴,王春芳.rhGM-CSF联合氨磷汀治疗放射性口腔黏膜炎的临床疗效及对外周血淋巴细胞亚群的影响[J].现代生物医学进展英文版,2022,(6):1102-1106. |
| rhGM-CSF联合氨磷汀治疗放射性口腔黏膜炎的临床疗效及对外周血淋巴细胞亚群的影响 |
| Clinical Efficacy of Recombinant Human Granulocyte Macrophage Colony Stimulating Factor Combined with Amifostine in the Treatment of Radiation Oral Mucositis and Its Influence on Peripheral Blood Lymphocyte Subsets |
| Received:November 01, 2021 Revised:January 23, 2022 |
| DOI：10.13241/j.cnki.pmb.2022.06.022 |
| 中文关键词: 重组人粒细胞/巨噬细胞集落刺激因子 氨磷汀 放射性口腔黏膜炎 淋巴细胞 |
| 英文关键词: Recombinant human granulocyte/macrophage colony stimulating factor Amifostine Radiation oral mucositis Lymphocyte |
| 基金项目:湖北省陈孝平科技发展基金项目（CXPJJH11800005-07） |
|
| Hits: 712 |
| Download times: 422 |
| 中文摘要: |
| 摘要 目的：研究重组人粒细胞/巨噬细胞集落刺激因子（rhGM-CSF）联合氨磷汀治疗放射性口腔黏膜炎患者的临床治疗疗效以及对外周血淋巴细胞亚群的影响。方法：选取2019年1月到2020年12月在我院接收治疗的放射性口腔黏膜炎患者60例，随机分为对照组和rhGM-CSF组两组，每组30例。对照组接受静脉滴注氨磷汀治疗，rhGM-CSF组接受rhGM-CSF漱口液漱口联合静脉滴注氨磷汀治疗。比较两组患者临床治疗疗效、治疗后口腔黏膜炎评分、疼痛评分、吞咽功能、血清炎症因子以及外周血淋巴细胞亚型。结果：（1）rhGM-CSF组患者临床治愈率和治疗总有效率分别为26.67 %和90.00 %，均高于对照组6.67 %临床治愈率和70.00 %临床治疗总有效率（P<0.05）。（2）治疗后，rhGM-CSF组口腔黏膜炎评分、疼痛评分、吞咽功能、血清干扰素-γ（IFN-γ）、肿瘤坏死因子（TNF-α）和白介素-6（IL-6）含量均显著低于对照组患者（P<0.05）。（3）rhGM-CSF组患者治疗后外周血CD3+T淋巴细胞与对照组比较无差异（P>0.05），外周血CD4+和CD4+/CD8+T淋巴细胞亚群显著高于对照组患者，而CD8+T淋巴细胞亚群显著低于对照组患者（P<0.05）。结论：rhGM-CSF漱口液联合静脉滴注氨磷汀治疗治疗放射性口腔黏膜炎临床疗效更优，有助于减轻患者外周血炎症反应，增强细胞免疫功能。 |
| 英文摘要: |
| ABSTRACT Objective: To study the clinical therapeutic effect of recombinant human granulocyte/macrophage colony stimulating factor (rhGM-CSF) combined with amifostine in the treatment of patients with radiation oral mucositis and the effect of peripheral blood lymphocyte subsets. Methods: A total of 60 patients with radiation oral mucositis who were treated in our hospital from January 2019 to December 2020 were selected and randomly divided into two groups: control group and rhGM-CSF group, with 30 patients in each group. Patients in the control group received intravenous infusion of amifostine, and patients in the rhGM-CSF group received rhGM-CSF mouthwash combined with intravenous infusion of amifostine. To compare the clinical treatment efficacy, oral mucositis score, pain score, swallowing function, serum inflammatory factors, and peripheral blood lymphocyte subtypes between the two groups of patients after treatment. Results: (1) The clinical cure rate and total effective rate of treatment in the rhGM-CSF group were 26.67 % and 90.00 %, respectively, which were significantly higher than the 6.67 % clinical cure rate and 70.00 % total effective rate of clinical treatment in the control group (P<0.05). (2) After treatment, the oral mucositis score, pain score, swallowing function, serum IFN-γ, TNF-α and IL-6 levels in the rhGM-CSF group were significantly lower than those in the control group (P<0.05). (3) The peripheral blood CD3+ T lymphocytes of the rhGM-CSF group were not significantly different from the control group after treatment (P>0.05), and the peripheral blood CD4+ and CD4+/CD8+T lymphocyte subsets were significantly lower than those of the control group (P<0.05), and the CD8+T lymphocyte subsets were significantly higher than those in the control group(P<0.05). Conclusion: rhGM-CSF mouthwash combined with intravenous infusion of amifostine has a better clinical effect in the treatment of radiation oral mucositis, which helps to reduce the patient's peripheral blood inflammation and enhance the patient's cellular immune function. |
|
View Full Text
View/Add Comment Download reader |
| Close |
